Roivant Sciences Ltd., Ten Percent Owner at Arbutus Biopharma, holds 79.81M shares in Immunovant (Ticker: IMVT), holds 18.58M shares in Sio Gene Therapies (Ticker: SIOX), holds 0.00 shares in Myovant Sciences (Ticker: MYOV). Most recently, Roivant Sciences Ltd. Bought ― shares of Immunovant on Oct 04, 2023 for an estimated value of 58.00M.
What was Roivant Sciences Ltd.’s latest transaction?
Roivant Sciences Ltd. latest transaction was an Informative Buy of $58.00M.
What was Roivant Sciences Ltd.'s most profitable transaction?
Roivant Sciences Ltd.’s most profitable transaction was an Informative Buy of IMVT stock on October 7, 2022. The return on the trade was 298.50%.
What is Roivant Sciences Ltd.'s role in Arbutus Biopharma?
Roivant Sciences Ltd.'s role in Arbutus Biopharma is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.